Citations

Mayo Clinic

Showing 10 of 108551 citations.

Epitome: Maximizing the Productive Interface Between the Clinical Microbiologist and the Infectious Disease Clinician
Rosenblatt, Jon E.

American Journal of Clinical Pathology | February 24, 2016 | Volume: 90 | Issue: 3 | Pages: 355-357

10.1093/ajcp/90.3.355 | PMID 3414607 Get It

The Authors’ Reply
Pierre, Robert V.

American Journal of Clinical Pathology | February 24, 2016 | Volume: 89 | Issue: 2 | Pages: 292-293

10.1093/ajcp/89.2.292a Get It

Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
Yao, Xiaoxi , Abraham, Neena S. , Montori, Víctor M. , Sangaralingham, Lindsey R. , Shah, Nilay D. , Alexander, G. Caleb , Crown, William H. , Gersh, Bernard J. , Noseworthy, Peter A. , Montori, Victor M , Yao, Xiaoxi

Journal of the American Heart Association | February 24, 2016 | Volume: 5 | Issue: 2 | Pages: No page available

10.1161/jaha.115.003074 | PMID 26908412 Get It

Background In comparison to warfarin, non–vitamin K antagonist oral anticoagulants ( NOAC s) have the advantages of ease of dosing, fewer drug interactions, and lack of need for ongoing monitoring. We sought to evaluate whether these advantages translate to improved adherence and whether adherence is associated with improved outcomes in patients with atrial fibrillation. Methods and Results We performed a retrospective cohort analysis by using a large US commercial insurance database to identify 64 661 patients with atrial fibrillation who initiated warfarin, dabigatran, rivaroxaban, or apixaban treatment between November 1, 2010, and December 31, 2014. During a median of 1.1 y of follow‐up, 47.5% of NOAC patients had a proportion of days covered of ≥80%, compared with 40.2% in warfarin patients ( P <0.001). Patients with CHA 2 DS 2 ‐ VAS c (risk based on the presence of congestive heart failure, hypertension age 65–74 y, age ≥75 y, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, sex category) score ≥4 were at increased risk of stroke when they were not taking anticoagulation ≥1 month versus <1 week (1–3 months: hazard ratio [ HR ] 1.96, 3–6 months: HR 2.64, ≥6 months: HR 3.66; all P <0.001). Patients with CHA 2 DS 2 ‐ VAS c score 2 or 3 were at increased risk of stroke when they were not taking anticoagulation ≥6 months ( HR 2.73, P <0.001). In these patients with CHA 2 DS 2 ‐ VAS c score ≥2, nonadherence was not associated with intracranial hemorrhage. Among patients with CHA 2 DS 2 ‐ VAS c score 0 or 1, time not taking anticoagulation was not associated with stroke, but not taking anticoagulation ≥3 months was associated with a significant reduction of bleeding. Conclusions Adherence to anticoagulation is poor in practice and may be modestly improved with NOAC s. Adherence to therapy appears to be most important in patients with CHA 2 DS 2 ‐ VAS c score ≥2, whereas the benefits of anticoagulation may not outweigh the harms in patients with CHA 2 DS 2 ‐ VAS c score 0 or 1.
Durability of Hearing Preservation after Cochlear Implantation with Conventional‐Length Electrodes and Scala Tympani Insertion
Sweeney, Alex D. , Hunter, Jacob B. , Carlson, Matthew L. , Bennett, Marc , Gifford, René H. , Noble, Jack H. , Haynes, David S. , Labadie, Robert F. , Wanna, George B. , Rivas, Alejandro , Hunter, Jacob B

Otolaryngology–Head and Neck Surgery | February 23, 2016 | Volume: 154 | Issue: 5 | Pages: 907-913

10.1177/0194599816630545 | PMID 26908553 Get It

ObjectivesTo analyze factors that influence hearing preservation over time in cochlear implant recipients with conventional‐length electrode arrays located entirely within the scala tympani.Study DesignCase series with planned chart review.SettingSingle tertiary academic referral center.Subjects and MethodsA retrospective review was performed to analyze a subgroup of cochlear implant recipients with residual acoustic hearing. Patients were included in the study only if their electrode arrays remained fully in the scala tympani after insertion and serviceable acoustic hearing (≤80 dB at 250 Hz) was preserved. Electrode array location was verified through a validated radiographic assessment tool. Patients with <6 months of audiologic follow‐up were excluded. The main outcome measure was change in acoustic hearing thresholds from implant activation to the last available follow‐up.ResultsA total of 16 cases met inclusion criteria (median age, 70.6 years; range, 29.4‐82.2; 50% female). The average follow‐up was 18.0 months (median, 16.1; range, 6.2‐36.4). Patients with a lateral wall electrode array were more likely to have stable acoustic thresholds over time (P <. 05). Positive correlations were seen between continued hearing loss following activation and larger initial postoperative acoustic threshold shifts, though statistical significance was not achieved. Age, sex, and noise exposure had no significant influence on continued hearing preservation over time.ConclusionsTo control for hearing loss associated with interscalar excursion during cochlear implantation, the present study evaluated patients only with conventional electrode arrays located entirely within the scala tympani. In this group, the style of electrode array may influence residual hearing preservation over time.
Impaired Cognition and Brain Atrophy Decades After Hypertensive Pregnancy Disorders
Mielke, Michelle M. , Milić, Nataša , Weissgerber, Tracey L. , Kantarci, Kejal , Windham, B. Gwen , Simpson, Brittany , White, Wendy M, Simpson, Brittany N, Turner, Stephen T. , Garovic, Vesna D. , White, Wendy , Mosley, Thomas H. , Weissgerber, Tracey L , Milic, N , Mielke, Michelle M , Kantarci, Kejal

Circulation: Cardiovascular Quality and Outcomes | February 23, 2016 | Volume: 9 | Issue: 2_suppl_1 | Pages: No page available

10.1161/circoutcomes.115.002461 | PMID 26908863 Get It

Background— Hypertensive pregnancy disorders have been associated with subjective cognitive complaints or brain white-matter lesions 5 to 10 years after the hypertensive pregnancy. The long-term effects of hypertensive pregnancies on brain structure and cognitive function remain unknown. Methods and Results— This study included 1279 women who participated in the Family Blood Pressure Project Genetic Epidemiology Network of Arteriopathy (GENOA) study. As part of the ancillary Genetics of Microangiopathic Brain Injury (GMBI) study, a neurocognitive battery was administered; 1075 also had a brain magnetic resonance imaging. A history of a hypertensive pregnancy disorder was obtained by a self-report using a validated questionnaire. Linear models fit with generalized estimating equations were used to assess the association between hypertensive pregnancy disorders and cognition, adjusting for age, race, education, body mass index, smoking, current hypertension, hypertension duration, and family history of hypertension. Regression models for the brain magnetic resonance imaging outcomes also were adjusted for total intracranial volume. Women with histories of hypertensive pregnancy disorders performed worse on all measures of processing speed (Digital Symbol Substitution Test [mean score, 41.2 versus 43.4; P =0.005], Trail Making Test Part A [mean seconds, 45.1 versus 42.2; P =0.035], and Stroop [mean score, 173.9 versus 181.0; P =0.002]) and had smaller brain volumes compared with women with histories of normotensive pregnancies (286 versus 297; P =0.023). Conclusions— Hypertensive pregnancy disorders are associated with worse performance on tests of processing speed and smaller brain volumes decades later. Population-based studies are needed to provide critical insight as to the contribution of hypertensive pregnancies to risk of cognitive decline and dementia.
Dynamic cycling in atrial size and flow during obstructive apnoea
Cepeda-Valery, Beatriz, Codolosa, Nicolas, Orban, Marek , Samuel, Solomon Praveen , Pressman, Gregg S. , Somers, Virend K.

Open Heart | February 23, 2016 | Volume: 3 | Issue: 1 | Pages: e000348

10.1136/openhrt-2015-000348 | PMID 27127636 Get It

Objective Obstructive sleep apnoea (OSA) is strongly associated with cardiovascular disease. However, acute cardiovascular effects of repetitive airway obstruction are poorly understood. While past research used a sustained Mueller manoeuver to simulate OSA we employed a series of gasping efforts to better simulate true obstructive apnoeas. This report describes acute changes in cardiac anatomy and flow related to sudden changes in intrathoracic pressure. Methods and results 26 healthy, normal weight participants performed 5–6 gasping efforts (target intrathoracic pressure −40 mm Hg) while undergoing Doppler echocardiography. 14 participants had sufficient echocardiographic images to allow comparison of atrial areas during the manoeuver with baseline measurements. Mitral and tricuspid E-wave and A-wave velocities postmanoeuver were compared with baseline in all participants. Average atrial areas changed little during the manoeuver, but variance in both atrial areas was significantly greater than baseline. Further, an inverse relationship was noted with left atrial collapse and right atrial enlargement at onset of inspiratory effort. Significant inverse changes were noted in Doppler flow when comparing the first beat postmanoeuver (pMM1) with baseline. Mitral E-wave velocity increased 9.1 cm/s while tricuspid E-wave velocity decreased 7.0 cm/s; by the eighth beat postmanoeuver (pMM8) values were not different from baseline. Mitral and tricuspid A-wave velocities were not different from baseline at pMM1, but both were significantly higher by pMM8. Conclusions Repetitive obstructive apnoeas produce dynamic, inverse changes in atrial size and Doppler flow across the atrioventricular valves. These observations have important implications for understanding the pathophysiology of OSA.
Multidrug-Resistant Tuberculosis and Its Association with Adrenal Insufficiency: Assessment with the Low-Dose ACTH Stimulation Test
Rodríguez‐Gutiérrez, René , Rendón, Adrián , Barrera–Sánchez, Maximiliano , Reyna, Erick Carlos , Álvarez‐Villalobos, Neri Alejandro , González-Saldivar, Gloria, González‐González, José Gerardo , González-Saldívar, Gerardo , González-Saldivar, Gloria, González-González, José Gerardo , Álvarez-Villalobos, Neri A

International Journal of Endocrinology | February 23, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-7

10.1155/2016/9051865 | PMID 27006656 Get It

Background. Multidrug-resistant tuberculosis (MDR-TB) is a major public health care concern that affects the life of millions of people around the world. The association of tuberculosis and adrenal insufficiency is well known; however, it is thought to be less prevalent every time. A spike in TB incidence and a lack of evidence of this association in patients with MDR-TB call for reassessment of an illness (adrenal dysfunction) that if not diagnosed could seriously jeopardize patients’ health.Objective. To determine the prevalence of adrenocortical insufficiency in patients with MDR-TB using the low-dose (1 μg) ACTH stimulation test at baseline and at 6–12 months of follow-up after antituberculosis treatment and culture conversion.Methods. A total of 48 men or women, aged ≥18 years (HIV-negative patients diagnosed with pulmonary MDR-TB) were included in this prospective observational study. Blood samples for serum cortisol were taken at baseline and 30 and 60 minutes after 1 μg ACTH stimulation at our tertiary level university hospital before and after antituberculosis treatment.Results. Forty-seven percent of subjects had primary MDR-TB; 43.8% had type 2 diabetes; none were HIV-positive. We found at enrollment 2 cases (4.2%) of adrenal insufficiency taking 500 nmol/L as the standard cutoff point value and 4 cases (8.3%) alternatively, using 550 nmol/L. After antituberculosis intensive phase drug-treatment and a negative mycobacterial culture (10.2±3.6months) adrenocortical function was restored in all cases.Conclusions. In patients with MDR-TB, using the low-dose ACTH stimulation test, a low prevalence of mild adrenal insufficiency was observed. After antituberculosis treatment adrenal function was restored in all cases. Given the increasing and worrying epidemic of MDR-TB these findings have important clinical implications that may help clinicians and patients make better decisions when deciding to test for adrenocortical dysfunction or treat insufficient stimulated cortisol levels in the setting of MDR-TB.
Iron in Alzheimer's and Control Hippocampi - Mössbauer, Atomic Absorption and ELISA Studies
Gała̧zka‐Friedman, J. , Bauminger, E. R., Szlachta, Karol , Tomasiuk, R., Jaklewicz, Andrzej, Kaplińska, Katarzyna, Friedman, A. , Koziorowski, Dariusz , Wszołek, Zbigniew K. , Dickson, Dennis W.

Acta Physica Polonica A | February 23, 2016 | Volume: 119 | Issue: 1 | Pages: 81-83

10.12693/aphyspola.119.81 Get It

Unique plasma metabolomic signatures of individuals with inherited disorders of long‐chain fatty acid oxidation
McCoin, Colin S. , Piccolo, Brian D. , Knotts, Trina A. , Matern, Dietrich , Gillingham, Melanie B. , Adams, Sean H. , Vockley, Jerry , Gillingham, Melanie B

Journal of Inherited Metabolic Disease | February 23, 2016 | Volume: 39 | Issue: 3 | Pages: 399-408

10.1007/s10545-016-9915-3 | PMID 26907176 Get It

AbstractBlood and urine acylcarnitine profiles are commonly used to diagnose long‐chain fatty acid oxidation disorders (FAOD: i.e., long‐chain hydroxy‐acyl‐CoA dehydrogenase [LCHAD] and carnitine palmitoyltransferase 2 [CPT2] deficiency), but the global metabolic impact of long‐chain FAOD has not been reported. We utilized untargeted metabolomics to characterize plasma metabolites in 12 overnight‐fasted individuals with FAOD (10 LCHAD, two CPT2) and 11 healthy age‐, sex‐, and body mass index (BMI)‐matched controls, with the caveat that individuals with FAOD consume a low‐fat diet supplemented with medium‐chain triglycerides (MCT) while matched controls consume a typical American diet. In plasma 832 metabolites were identified, and partial least squared‐discriminant analysis (PLS‐DA) identified 114 non‐acylcarnitine variables that discriminated FAOD subjects and controls. FAOD individuals had significantly higher triglycerides and lower specific phosphatidylethanolamines, ceramides, and sphingomyelins. Differences in phosphatidylcholines were also found but the directionality differed by metabolite species. Further, there were few differences in non‐lipid metabolites, indicating the metabolic impact of FAOD specifically on lipid pathways. This analysis provides evidence that LCHAD/CPT2 deficiency significantly alters complex lipid pathway flux. This metabolic signature may provide new clinical tools capable of confirming or diagnosing FAOD, even in subjects with a mild phenotype, and may provide clues regarding the biochemical and metabolic impact of FAOD that is relevant to the etiology of FAOD symptoms.
Longitudinal decline in mild‐to‐moderate Alzheimer's disease: Analyses of placebo data from clinical trials
Thomas, Ronald G. , Albert, Marilyn, Petersen, Ronald C. , Aisen, Paul

Alzheimer's & Dementia | February 23, 2016 | Volume: 12 | Issue: 5 | Pages: 598-603

10.1016/j.jalz.2016.01.002 | PMID 26917500 Get It

AbstractIntroductionAccurate estimates of cognitive and clinical decline rates are essential to the design of clinical trials in Alzheimer's disease (AD) dementia.MethodsTo investigate the trajectories of individuals enrolled in therapeutic trials in mild‐to‐moderate AD, we analyzed the placebo arm data from 20 clinical trials including over 4500 subjects. We analyzed decline as measured by two cognitive instruments, the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAScog) and the Mini‐Mental State Examination, and one clinical rating scale, the Clinical Dementia Rating Sum of Boxes.ResultsTrajectories were generally similar across trials and nearly linear. Greater cognitive impairment at baseline, younger age, and greater education were associated with increased rate of cognitive decline. Effect sizes for the ADAScog were generated as a function of population characteristics.DiscussionThese data will inform the design of future studies of potential disease‐modifying therapies for mild‐to‐moderate AD dementia.